drugset / Trial / NCT05557565
A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, multicenter, phase II trial to evaluate the efficacy and safety of QL1706 in patients with recurrent or metastatic cervical cancer.
Timeline
- Start
- 2021-12-21
- Primary completion
- 2022-10-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |